Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cellectar Biosciences, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
newly diagnosed glioblastoma or recurrent/suspected recurrent glioblastoma
scheduled to undergo a clinically-indicated surgery or biopsy (specific cohorts)
ECOG performance status of 0 to 2 (Appendix C)
18 years of age or older
has the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits
has the ability to read, understand and provide written informed consent for the initiation of any study related procedures (or legal representative)
if female of childbearing potential must have a negative pregnancy test within 24 hours of enrollment
Women of childbearing potential and men who are able to father a child, must agree to use an effective method of contraception (e.g., oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device, Norplant, Depo-Provera) during the study and for 45 days following the last dose of the study drug.
You may not be if
ongoing grade 2 or greater toxicities due to previous therapies. However, tolerable grade 2 adverse (e.g. neuropathy) events may be allowed at the discretion of the investigator.
has following laboratory abnormalities
* Platelets \< 100,000/μL
* WBC \< 3000/μL
* Hematocrit \< 22%
* Serum creatinine \> 2.5 mg/dL
* ALT \> 1.5 x ULN
* Bilirubin \> 1.5 x ULN
ongoing chronic immunosuppressive therapy
history of hypersensitivity to iodine
any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise subject safety or interfere with the evaluation of the safety of the test drug
women of childbearing potential, or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trial
pregnancy or breast-feeding
inability to comply with the protocol
use of any investigational drug within 4 weeks of dosing (unless a longer time period is required by local regulations or the investigational agent)
